Contact us today to schedule your appointment and take the first step towards a more radiant, confident you
479 Between 2000 and 2023, the death rate from Alzheimer's increased 37% for people age 65 to 74, 38% for people age 75 to 84 and 65% for people age 85 and older
Dual GLP1 and GIP agonists Tirzepatide is a once weekly, subcutaneous, unimolecular dual RA (GLP-1 and GIP) which has comparable GIP receptor binding affinity to native GIP and 5 times lower GLP-1 receptor affinity than that of native GLP-1
Core Benefits and Mechanisms of BPC-157 Current research points to several potential therapeutic mechanisms for BPC-157, although human clinical data remains limited
Relying on B12 injections for weight loss without a confirmed deficiency is not supported by scientific evidence
If NAION is confirmed, treatment with semaglutide should be discontinued